million baht, in accordance with the consolidated financial statements as of September 30, 2019, which exceeded 0.03% but not over 3.00% of NTA. The Company has already disclosed information to the Stock

Page 1 of 4 No. RJH – SET 3/2020 24 February 2020 Subject : Management’s Discussion and Analysis for the 4th Quarter of 2019 To : The President The Stock Exchange of Thailand Rajthanee Hospital

Page 1 of 4 No. RJH – SET 14/2017 10 November 2017 Subject : Management Discussion and Analysis for the 3rd Quarter of 2017 ending 30 September 2017 To : The President The Stock Exchange of Thailand

(Translation) UAC.CS/002/2019 February 28, 2019 Subject: Explanation of the operating results for the year period ended December 31, 2018 To: President The Stock Exchange of Thailand Attachment

. DOD017/2562 May 8, 2019 Re: Management’s Discussion and Analysis (MD&A) of the Consolidated Financial Results for Quarter 1 of 2019 To: The President The Stock Exchange of Thailand DOD Biotech Public

Page 1 of 4 No. RJH – SET 8/2019 13 May 2019 Subject : Management’s Discussion and Analysis for the First Quarter of 2019 To : The President The Stock Exchange of Thailand Rajthanee Hospital Public

President The Stock Exchange of Thailand 1. Overview financial performance of E for L Aim Public Company Limited (“EFORL” or “the Company”) and its subsidiaries (collectively as “the Companies”) for Q1/2019

S&P MD&A Q2_2019-Eng Ref. POL. 085/2019 August 8th 2019 Re: Clarification of the Performance of S & P Syndicate Public Company Limited Dear The President The Stock Exchange of Thailand S & P

Ref. POL. 125/2019 November 8th 2019 Re: Clarification of the Performance of S & P Syndicate Public Company Limited Dear The President The Stock Exchange of Thailand S & P Syndicate Public Company

Page 1 of 4 No. RJH – SET 16/2019 11 November 2019 Subject : Management’s Discussion and Analysis for the 3rd Quarter of 2019 To : The President The Stock Exchange of Thailand Rajthanee Hospital